BSE · 511523 · Pharmaceuticals
Veerhealth Care Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹18 Cr with net profit ₹0 Cr — a 2.19% net margin, versus 2.78% the period before.
Shareholding
As of 2026-06-30
- Promoter31.91%
- Public68.09%
9,315 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.53× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — ESM · ESM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Trading · ranked #213 of 666 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Adani Enterprises Limited | ₹3,96,659 Cr | 24.35 | 4.87 | 3.42% | 9.3% |
| Avenue Supermarts Limited | ₹2,52,648 Cr | 383.94 | 10.32 | 12.14% | 4.32% |
| Trent Ltd. | ₹1,59,927 Cr | 92.65 | 22.9 | 24.62% | 8.57% |
| FSN E-Commerce Ventures Ltd. | ₹95,580 Cr | 1236.11 | 66.46 | 13.87% | 1.99% |
| Vishal Mega Mart Limited | ₹50,539 Cr | 56.78 | 6.81 | 11.32% | 6.61% |
| Premier Energies Limited | ₹44,610 Cr | 29.55 | 10.36 | 35.05% | 19.3% |
| Aegis Logistics Limited | ₹43,850 Cr | 106.87 | 7.24 | 14.83% | 10.78% |
| Aditya Infotech Limited | ₹38,417 Cr | 226.85 | 20.46 | 19.61% | 8.72% |
| Redington Limited | ₹24,309 Cr | 15.27 | 2.39 | 14.67% | 1.25% |
| Honasa Consumer Limited | ₹14,510 Cr | 209.37 | 10.28 | 14.16% | 8.36% |
| Veerhealth Care Limited(this company) | ₹84 Cr | 123.71 | 3.67 | 2.96% | 1.66% |
AI analysis
AI-generated · google/gemini-2.5-flashVeerhealth Care Limited has a market capitalization of Rs 82 Cr. The company reported revenue of Rs 17.89 Cr and a net profit margin of 166.2%. The earnings per share (EPS) is Rs 0.34 and the price-to-earnings (PE) ratio is 120.79. The book value per share is Rs 11.46.
Positives
- +The company has a high return on equity (ROE) of 295.8%.
- +The debt-to-equity ratio is low at 0.11.
- +Promoter shareholding is not pledged (0%).
Negatives
- −Revenue growth for the last fiscal period is not available.
- −The profit margin of 166.2% seems abnormally high and may indicate a one-time gain or accounting anomaly.
- −Net profit saw a decline in the recent March 2025 quarter to -Rs 0.1 Cr from Rs 0.07 Cr in December 2024.
- −The company is under ESM surveillance, indicating increased monitoring.
- −Earnings per share (EPS) have shown fluctuation, declining from Rs 1.52 in Mar 2023 to Rs 0.20 in Mar 2025.
Financial Performance
The company's revenue increased to Rs 17.8892 Cr in Mar 2025 from Rs 14.6128 Cr in Mar 2024. Net profit decreased to Rs 0.3914 Cr in Mar 2025 from Rs 0.4061 Cr in Mar 2024. Earnings per share (EPS) declined to Rs 0.20 in Mar 2025 from Rs 0.21 in Mar 2024.
Profitability & Returns
Veerhealth Care Limited recorded a return on equity (ROE) of 295.8% and a return on capital employed (ROCE) of 6.55%. The net profit margin stands at 166.2%. The EPS for the latest period is Rs 0.34.
Balance Sheet
The company has a debt-to-equity ratio of 0.11, indicating low leverage. The book value per share is Rs 11.46. No information on non-current assets or liabilities is provided in the available data.
Ownership & Pledges
There are no shares pledged by the promoters. The number of shareholders is 10027.
Regulatory & Surveillance
Veerhealth Care Limited is currently under the ESM (Enhanced Surveillance Measure) framework, specifically ESM Stage 1. This includes surveillance measures such as additional monitoring by the एक्सचेंज authorities.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.